Biomea Fusion Stock Quote BMEA - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

4.05

Bid

3.97

Ask

4.03

Volume

793,327

3.90 Day's Range 4.30

3.65 52 Week Range 20.21

Market Cap

146.767M

Previous Close

4.08

Open

4.09

Last Trade

4.0485

Last Trade Time

Financial Volume

$ 3,203,808

VWAP

4.0384

Average Volume (3m)

849,169

Shares Outstanding

36,238,687

Dividend Yield

PE Ratio

-1.24

Earnings Per Share (EPS)

-3.24

Revenue

Net Profit

-117.26M

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.biomeafusion.com

Headquarters

Wilmington, Delaware, USA

Founded

Biomea Fusion Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BMEA. The last closing price for Biomea Fusion was $4.08. Over the last year, Biomea Fusion shares have traded in a share price range of $ 3.65 to $ 20.21.

Biomea Fusion currently has 36,238,687 shares outstanding. The market capitalization of Biomea Fusion is $147.85 million. Biomea Fusion has a price to earnings ratio (PE ratio) of -1.24.

Overall Flow

Bearish

Net Premium

-55k

Calls / Puts

0.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

Form 8-K - Current report

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response...

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression...

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and...

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...

Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Icovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type 2 Diabetes Patients Characterized by Insulin Deficiency 32 patients from the 100mg and...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.05	-1.21951219512	4.1	4.29	3.89	590847	4.10804391	CS
4	-3.13	-43.5933147632	7.18	7.46	3.81	1080069	5.0006792	CS
12	-6.15	-60.2941176471	10.2	13.07	3.81	849169	7.57161127	CS
26	-0.45	-10	4.5	13.07	3.81	811571	7.21133549	CS
52	-11.32	-73.6499674691	15.37	20.21	3.65	994765	9.86231695	CS
156	-3.75	-48.0769230769	7.8	43.69	2.84	639417	14.6888191	CS
260	-15.95	-79.75	20	43.69	2.84	544465	14.63307642	CS

BMEA - Frequently Asked Questions (FAQ)

What is the current Biomea Fusion share price?

The current share price of Biomea Fusion is $ 4.05

How many Biomea Fusion shares are in issue?

Biomea Fusion has 36,238,687 shares in issue

What is the market cap of Biomea Fusion?

The market capitalisation of Biomea Fusion is USD 147.85M

What is the 1 year trading range for Biomea Fusion share price?

Biomea Fusion has traded in the range of $ 3.65 to $ 20.21 during the past year

What is the PE ratio of Biomea Fusion?

The price to earnings ratio of Biomea Fusion is -1.24

What is the reporting currency for Biomea Fusion?

Biomea Fusion reports financial results in USD

What is the latest annual profit for Biomea Fusion?

The latest annual profit of Biomea Fusion is USD -117.26M

What is the registered address of Biomea Fusion?

The registered address for Biomea Fusion is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Biomea Fusion website address?

The website address for Biomea Fusion is www.biomeafusion.com

Which industry sector does Biomea Fusion operate in?

Biomea Fusion operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
INTZIntrusion Inc	$ 2.167 (381.56%)	189.59M
AILEiLearningEngines Inc	$ 0.5932 (267.31%)	563.26M
HUBCWHub Cyber Security Ltd	$ 0.035 (250.00%)	2.79M
GTIGraphjet Technology	$ 0.967551 (185.83%)	398.94M
LITMSnow Lake Resources Ltd	$ 1.61 (82.95%)	131.96M
NEUPNeuphoria Therapeutics Inc	$ 4.11 (-92.30%)	936.47k
VIRXViracta Therapeutics Inc	$ 0.16 (-32.49%)	9.31M
PRFXPainReform Ltd	$ 3.48 (-28.98%)	926.19k
AIREreAlpha Tech Corporation	$ 2.56 (-28.49%)	8.26M
AVGRAvinger Inc	$ 0.9721 (-24.05%)	2.11M
AILEiLearningEngines Inc	$ 0.5932 (267.31%)	563.26M
GTIGraphjet Technology	$ 0.967551 (185.83%)	398.94M
RGTIRigetti Computing Inc	$ 17.08 (10.62%)	305.78M
XTIAXTI Aerospace Inc	$ 0.03935 (-1.63%)	267.99M
QSIQuantum Si Inc	$ 3.585 (66.74%)	256.01M